Abiopharma

🔍 Rodman David Malcom (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-01-20

Detailed Transactions and Holdings:

• Acquired 416 shares of Common Stock at $15.44 per share (Direct)
  Date: 2026-01-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 50,853.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 416 shares of Common Stock at $32.1 per share (Direct)
  Date: 2026-01-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,437.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 416 shares of Stock Option at $15.44 per share (Derivative)
  Date: 2026-01-20 | Code: M | Expires: 2033-03-17 | equity_swap_involved: 0 | shares_owned_after: 5,834.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• F2: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.